Oncology: Prostate
Monday, May 18
IP76-01: Combined target plus systematic versus only target prostate biopsy: impact on oncologic and functional outcomes after radical prostatectomy
IP76-02: MRI/Ultrasound Fusion–Targeted Biopsy Alone Versus Combined Systematic and Targeted Biopsy in Prostate Cancer Diagnosis: A Multicenter Prospective Trial
IP76-03: Strategic Sampling in Transperineal Prostate Biopsy: Evaluating the Benefits of Targeted Biopsy alone vs. Targeted Plus Random Biopsy
IP76-05: Evolving National Trends in the Use of MRI Prior to Prostate Biopsy and the Subsequent Impact on Prostate Cancer Diagnosis
IP76-06: Prostate Imaging Standards for Screening Magnetic Resonance Imaging (PRISM): international consensus recommendations
IP76-07: Reassessing the Role of Contralateral Sampling in MRI-Fusion Transperineal Prostate Biopsy For Unilateral MRI Lesions
IP76-08: MRI-Targeted biopsy with index lesion ipsilateral or bilateral systematic biopsies for Prostate Cancer diagnosis: a multicenter non-inferiority paired-design trial
IP76-09: Individualized precision prostate biopsy strategy for patients with PI-RADS score 2: a retrospective multicenter study
IP76-10: Micro-Ultrasound in MRI-Negative or Equivocal Prostate Cancer: Early Proficiency and Diagnostic Added Value in a 262-Case Real-World Series
IP76-11: Germline testing for prostate cancer patients: Evidence-based evaluation of genes recommended by NCCN guidelines
IP76-12: Adherence to Germline Testing and Provider Patterns in Eligible Men with Prostate Cancer at an Urban Cancer Center.
IP76-14: Are prostate cancer risk calculators valid for the Mexican population?
IP76-16: Predictors of Prostate Cancer Screening by Primary Care Providers seeing Patients due for Screening
IP76-17: The impact of missing an appropriate work-up opportunity in patients presenting with an elevated PSA on their long-term oncological outcomes
IP76-18: Immediate release of prostate biopsy results to patients in the electronic age: are we helping or harming patients?
IP76-19: Progression to Clinically Significant Prostate Cancer in Patients with Isolated HGPIN/ASAP compared to Grade Group 1 Disease
IP76-20: PSA Density-Guided Approach to Systematic vs. MRI-Targeted Transperineal Biopsy For Detection of Prostate Cancer
IP76-21: Can We Rely on PSA Density Alone in Diagnosing Clinically Significant Prostate Cancer? A Comprehensive Analysis of 961 Consecutive Transperineal Biopsies from a UK High Volume Centre
IP76-22: Enhancing Prostate Cancer Diagnosis: Does PSAD Integration Improve MRI Reliability? Analysis of 961 Biopsies
IP76-23: A Urine-Based DNA Methylation Assay for Detection of Clinically Significant Prostate Cancer
IP76-24: Value of Stockholm3 in Men with PSA 1.5–3 ng/mL: Evidence from the Swedish Prostate Cancer Registry
IP76-25: PCaMEx: A Mixture-of-Experts AI Framework for Whole-Slide Prostate Cancer Pathology Diagnosis in Veterans
IP76-26: Evaluating the Clinical Utility of the PROSTest, a Blood Multigene mRNA Signature, for Biopsy Stratification in At-Risk Subjects
IP76-27: Stockholm3 Test Performance for Reducing MRI in Organised Prostate Cancer Testing (OPT)
IP76-28: Confirmation of BIK and SAMHD1 as prostate cancer susceptibility genes
Registered attendees
KS
Kristian Stensland
Assistant ProfessorUniversity of Michigan